A fascinating patent application by Hologic, Inc. using CDs in enzyme formulations for nucleic acid amplification. The compositions are also useful in mitigating the inhibitory effect of sample extraction detergents.
See the full patent on PatentScope
This is a real delicacy for #carbohydrates and #cyclodextrin lovers from the group of Graziella Vecchio – Università di Catania (Luana La Piana, Livia Basile, Chiara Ragusa et al.). They synthesize and characterize two new β and γ-cyclodextrin dimers and compare their complexation behavior. The two cavities in the same molecule significantly improve the stability of inclusion complexes – particularly investigated cholic acid, cholesterol, and doxorubicin as guests.
While the mainstream use of CDs in pharma is solubilization, improving chemical stability is close to 2nd most popular, even though it is more complicated to achieve. This patent by Thorsteinn Loftsson (Oculis S.A.) and Zoltán Fülöp encorporates a nice case study of preventing the oxidation of corticosteroids.
See the full patent on PatentScope
This is a little reminder of the great potential to use these compounds (especially # cholesterol-loaded methyl-beta-cyclodextrin) to improve fertilization capacity. The fertilization and development ability of vitrified bovine oocytes were improved by the combination treatment of JUNO mRNA microinjection and CLC/MβCD – Chinese Academy of Agricultural Sciences
Cyclo Therapeutics, Inc. announces first patient dosed in Phase 2b study of Trappsol® Cyclo™ for treating early Alzheimer’s disease.
Trappsol® Cyclo™ is the Company’s proprietary formulation of hydroxypropyl beta-cyclodextrin. In multiple clinical studies, it has shown encouraging results in effectively managing the transportation of cholesterol, a known defect in neurodegenerative diseases. Many known risk factors for Alzheimer’s disease are associated with cholesterol metabolism.
Cyclo Therapeutics is currently testing the same investigational Trappsol® Cyclo™ drug in Phase 3 clinical trial (TransportNPC™) and a long-term extension study for the treatment of Niemann-Pick disease Type C1, a rare, fatal, and progressive genetic disorder. Taking the place of the defective NPC1 protein, Trappsol® Cyclo™, with its cyclic structure, facilitates the transport of accumulated cholesterol out of cellular lysosomes so it can be further processed and excreted out of cells. With the biological similarities demonstrated between Niemann-Pick disease Type C1 and Alzheimer’s disease, including cholesterol accumulation in regions of the brain, elevated levels of Tau in cerebrospinal fluid (“CSF”), and amyloid plaques in the brain, the Company believes Trappsol® Cyclo™ has significant potential to be an effective treatment option for Alzheimer’s disease.
Read the full announcement here
ZyVersa Therapeutics Inc., developing, among others VAR200, a therapeutic 2-hydroxypropyl-beta-#cyclodextrin for FSGS, Alport syndrome, and diabetic kidney disease, just added two leading nephrologists to their Scientific Advisory Board.
We hope this will help move the program forward to follow this one-of-a-kind application of CDs with great excitement.
A great compilation on the controlled drug delivery mediated by cyclodextrin-based supramolecular self-assembled carriers: From design to clinical performances at Pharma Excipients International AG compiled by University POLITEHNICA of Bucharest (Jana Ghitman and Voicu Stefan Ioan)
Using CDs in variuous fields of drug delivery is getting more attention; here is a new application: CD-supported nanoparticles to carry intact CRISPR/CAS9 proteins by University of California, Los Angeles (Hsian-Rong Tseng, Qian Ban, zhu yazhen, Peng Yang)
A great review on a unique industrial application: Green β-cyclodextrin-based corrosion inhibitors from National University of Uzbekistan, University of South Africa/Universiteit van Suid-Afrika, Ibn Tofail University, Yeungnam University and Sidi Mohamed Ben Abdellah University
Lyle Isaacs and his team from University of Maryland has something fascinating to show. Not only have they published a potent supramolecular host for in vivo sequestration of methamphetamine and fentanyl (similar to the Sugammadex concept) but they also shared this cool video on the mechanism of action: UMD Researcher Creates Chemical Compound That Can Reverse Effects of Potentially Deadly Drugs – YouTube
This is how you should present science! Amazing!
Adam Brockett, Canjia Zhai, Shivangi Rastogi, Volker Briken